American Association for Cancer Research
Browse
00085472can076595-sup-sfi_g4.pdf (154.82 kB)

Supplementary Figure 4 from A Gene Signature Predicting for Survival in Suboptimally Debulked Patients with Ovarian Cancer

Download (154.82 kB)
journal contribution
posted on 2023-03-30, 18:13 authored by Tomas Bonome, Douglas A. Levine, Joanna Shih, Mike Randonovich, Cindy A. Pise-Masison, Faina Bogomolniy, Laurent Ozbun, John Brady, J. Carl Barrett, Jeff Boyd, Michael J. Birrer
Supplementary Figure 4 from A Gene Signature Predicting for Survival in Suboptimally Debulked Patients with Ovarian Cancer

History

ARTICLE ABSTRACT

Despite the existence of morphologically indistinguishable disease, patients with advanced ovarian tumors display a broad range of survival end points. We hypothesize that gene expression profiling can identify a prognostic signature accounting for these distinct clinical outcomes. To resolve survival-associated loci, gene expression profiling was completed for an extensive set of 185 (90 optimal/95 suboptimal) primary ovarian tumors using the Affymetrix human U133A microarray. Cox regression analysis identified probe sets associated with survival in optimally and suboptimally debulked tumor sets at a P value of <0.01. Leave-one-out cross-validation was applied to each tumor cohort and confirmed by a permutation test. External validation was conducted by applying the gene signature to a publicly available array database of expression profiles of advanced stage suboptimally debulked tumors. The prognostic signature successfully classified the tumors according to survival for suboptimally (P = 0.0179) but not optimally debulked (P = 0.144) patients. The suboptimal gene signature was validated using the independent set of tumors (odds ratio, 8.75; P = 0.0146). To elucidate signaling events amenable to therapeutic intervention in suboptimally debulked patients, pathway analysis was completed for the top 57 survival-associated probe sets. For suboptimally debulked patients, confirmation of the predictive gene signature supports the existence of a clinically relevant predictor, as well as the possibility of novel therapeutic opportunities. Ultimately, the prognostic classifier defined for suboptimally debulked tumors may aid in the classification and enhancement of patient outcome for this high-risk population. [Cancer Res 2008;68(13):5478–86]

Usage metrics

    Cancer Research

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC